BRIDGE-1 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 impedes the proteasomal degradation pathway, which is essential for the turnover of many proteins, including BRIDGE-1. By inhibiting the proteasome, MG132 causes an accumulation of ubiquitinated proteins, indirectly preventing BRIDGE-1 from facilitating its normal proteolytic functions. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin specifically inhibits the proteasome's catalytic activity, which would result in the accumulation of proteins that are normally degraded. This accumulation can indirectly inhibit BRIDGE-1's function by disrupting the proteolytic processes it's involved in. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $137.00 $219.00 $449.00 $506.00 | 19 | |
Epoxomicin forms a covalent bond with the proteasome, leading to irreversible inhibition. The consequent build-up of proteins that require regulated degradation indirectly impairs the functional role of BRIDGE-1 in the proteasome complex. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib binds to the 26S proteasome with high affinity and specificity, inhibiting its chymotrypsin-like activity. This inhibition can interfere with the proteasome's ability to degrade substrates, a process in which BRIDGE-1 is involved, thereby indirectly inhibiting BRIDGE-1. | ||||||
Carfilzomib | 868540-17-4 | sc-396755 | 5 mg | $41.00 | ||
Carfilzomib irreversibly binds to and inhibits the proteasome's chymotrypsin-like site. This impedes the degradation of polyubiquitinated proteins, indirectly inhibiting BRIDGE-1 by disrupting the proteolytic cycle in which it participates. | ||||||
Oprozomib | 935888-69-0 | sc-477447 | 2.5 mg | $280.00 | ||
Oprozomib, an bioavailable proteasome inhibitor, targets and inhibits the activity of the proteasome. This inhibition can lead to an accumulation of proteins involved in various signaling pathways, indirectly inhibiting the function of BRIDGE-1 by altering proteasome dynamics. | ||||||
Delanzomib, free base | 847499-27-8 | sc-396774 sc-396774A | 5 mg 10 mg | $160.00 $300.00 | ||
Delanzomib is a boronic acid-based proteasome inhibitor. By inhibiting the proteasome, Delanzomib indirectly inhibits BRIDGE-1 by causing a build-up of proteins that BRIDGE-1 would normally help to degrade. | ||||||
Ixazomib | 1072833-77-2 | sc-489103 sc-489103A | 10 mg 50 mg | $311.00 $719.00 | ||
Ixazomib selectively and reversibly inhibits the 20S proteasome. The proteasome's reduced activity leads to an increase in undegraded proteins, which can indirectly inhibit the functional activity of BRIDGE-1 within the proteasome complex. | ||||||